INBX vs KMX · rev $1.3M vs P/E 19, rev $25.88B
Inhibrx Biosciences, Inc. (INBX) versus CarMax Inc (KMX) — a side-by-side from cached financials, not a winner call.
Inhibrx Biosciences, Inc. (INBX) is a biotechnology company listed on US.
CarMax Inc (KMX) is a auto & truck dealerships company listed on US.
Latest reported INBX revenue for 2025-12-31 was $1.3M. Net income was -$140.1M. Revenue was up 550.0% from 2024-12-31 to 2025-12-31. INBX currently screens at market cap $1.28B.
Latest reported KMX revenue for 2026-02-28 was $25.88B. Net income was $247.3M. Revenue was down 1.8% from 2025-02-28 to 2026-02-28. KMX currently screens at market cap $10.26B and trailing P/E 18.9.
INBX currently screens at market cap $1.28B. KMX currently screens at market cap $10.26B and trailing P/E 18.9.
Not investment advice. Open the INBX and KMX stock pages for the full models.
Not investment advice.